

Demonstration of the CAMARADES-NC3Rs Systematic Review Facility (SyRF)



SYSTEMATIC
Review Facility

30 March 2017

Gillian Currie

Outline

- **Previous CAMARADES database**
- **SyRF - Systematic Review Facility**
 - Educational resources for systematic review and meta-analysis
 - Online platform
 - Flexible for individual projects
- **Demonstration and learn to SyRF**




CAMARADES

- Collaborative **A**pproach to **M**eta-**A**nalysis and **R**eview of **A**nimal **D**ata from **E**xperimental **S**tudies
- Supporting framework for systematic review and meta-analysis of animal studies
- Look systematically across the modelling of a range of conditions
- Microsoft Access Data Repository
 - 40 Projects
 - 30 Diseases
 - 25,000 studies
 - from over 400,000 animals

Stages of Systematic Review and Meta-analysis



Toolbox for SyrF



http://syrf.org.uk

[LAUNCH SYRF](#)[HOME](#)[ABOUT US](#)[SYSTEMATIC REVIEW](#)[PROTOCOLS](#)[LIBRARY](#)[CONTACT US](#)

SYSTEMATIC
Review Facility

Welcome to the **CAMARADES-NC3Rs** Preclinical **Systematic Review & Meta-analysis Facility (SyRF)**

What is SyRF?

SyRF is a fully integrated online platform for performing systematic reviews of preclinical studies.

SyRF provides:

- Educational resources on how to conduct and report a systematic review
- Secure screening database, data repository and analysis applications
- Guidance on any aspect of preclinical systematic review and meta-analysis

How to use SyRF

- Use the SyRF website to learn about preclinical [systematic review](#) and ask questions or request assistance through our [helpdesk](#)
- Search published [protocols](#) to check if there is a review underway in your field of interest
- Publish your preclinical systematic review protocol in the SyRF [protocol repository](#)
- Find existing preclinical systematic reviews in our [systematic review library](#)

Systematic Review

[LAUNCH SYRF](#)[HOME](#)[ABOUT US](#)[SYSTEMATIC REVIEW](#)[PROTOCOLS](#)[LIBRARY](#)[CONTACT US](#)**NC
3R^s**

[What is a Systematic Review?](#)

[Step 1: Research Question](#)

[Step 2: Protocol](#)

[Step 3: Search Strategy](#)

[Step 4: Study Selection](#)

[Step 5: Data Extraction](#)

[Step 6: Study Quality](#)

[Step 7: Meta-Analysis](#)

[Step 8: Interpret the Results](#)

[Step 9: Final Publication](#)

What is a Systematic Review?

A systematic review is a literature review that involves systematically locating, appraising, and synthesising evidence from scientific studies to answer a defined research question based on pre-specified criteria.

What is a meta-analysis?

A method of combining quantitative results from individual studies identified through systematic review in an overall statistical analysis.


Why perform a systematic review of preclinical research?

- Provide an overview of available evidence
- Identify factors influencing treatment efficacy
- Identify knowledge gaps
- Inform experimental design of new studies
- Critically appraise study quality
- Reduce waste in future research

The results of preclinical systematic reviews can:

- Provide evidence to change research practice by identifying risks of bias in preclinical experiments
- Influence development of reporting guidelines and editorial policies
- Provide evidence to support reporting of positive, negative and neutral results through detection of publication bias

SyRF Traffic



Protocol development and registration

Systematic review library

[LAUNCH SYRF](#)[HOME](#)[ABOUT US](#)[SYSTEMATIC REVIEW](#)[PROTOCOLS](#)[LIBRARY](#)[CONTACT US](#)[NC3RS](#)

Systematic Review & Protocol Library

This is a repository for existing preclinical systematic reviews published in peer-reviewed journals. Search this library to check whether your research question has already been answered with a systematic review, to find a specific systematic review, or to get a broad overview of a topic or drug intervention.

Systematic reviews were identified using PubMed, Embase, Web of Science, and Evidence-based Preclinical Medicine databases. The library can be searched for a specific drug, intervention, animal or disease. A logo denotes the review was supported by SyRF and NC3RS.

[SEARCH](#)

Title: [Mouse models of diabetic retinopathy: systematic review of the literature]

Year: 3/1/2013

Author: Giocanti-Auregan A;Tadayoni R;Ahn L;Pena JT;D'Amico DJ;

Journal: J Fr Ophtalmol

Title: [The efficacy of hypertonic saline treatment in cardiopulmonary resuscitation in animal model with cardiac arrest: a Meta-analysis]

Year: 2015

Author: Li W;Xu J;Tan D;Yu X;

Journal: Zhonghua wei zhong bing ji jiu yi xue

Title: [The efficacy of traditional Chinese medicine in animal model of lung injury induced by paraquat: a meta-analysis]

Year: 6/1/2014

Author: Wang L;Hong G;Li D;Chen X;Han W;Lu Z;

Journal: Zhonghua Wei Zhong Bing Ji Jiu Yi Xue

Contact us



LAUNCH SYRF

HOME

ABOUT US

SYSTEMATIC REVIEW

PROTOCOLS

LIBRARY

CONTACT US



NC
3R^s

Contact Us

Name *

Email *

Institution*

Subject *

Message *

Launch SyRF



LAUNCH SYRF

HOME

ABOUT US

SYSTEMATIC REVIEW

PROTOCOLS

LIBRARY

CONTACT US



SYSTEMATIC
Review Facility

Welcome to the **CAMARADES-NC3Rs** Preclinical **Systematic Review & Meta-analysis Facility (SyRF)**

What is SyRF?

SyRF is a fully integrated online platform for performing systematic reviews of preclinical studies.

SyRF provides:

- Educational resources on how to conduct and report a systematic review
- Secure screening database, data repository and analysis applications
- Guidance on any aspect of preclinical systematic review and meta-analysis

How to use SyRF

- Use the SyRF website to learn about preclinical [systematic review](#) and ask questions or request assistance through our [helpdesk](#)
- Search published [protocols](#) to check if there is a review underway in your field of interest
- Publish your preclinical systematic review protocol in the SyRF [protocol repository](#)
- Find existing preclinical systematic reviews in our [systematic review library](#)

Protocol development and registration

An easily accessible resource to aid systematic review and meta-analysis of *in vivo* studies.



Login



SYSTEMATIC
Review Facility

Register.

Create a new account.

Email

First Name


Surname

Preferred Name


Password

Confirm password

Use another service to log in.



Gill's Projects



My Projects Public Projects

Gill's Projects

My Projects

Public



Neuropathic

Protocol

NP subset



IL-1 RA stro

Protocol

IL-1 RA update

Create project

Project Name

IL-1 RA stroke update

Protocol Url

https://drive.google.com/file/d/0B5x-sP1A05kgVWWYtX09RejBockE

*We strongly recommend that you register your Systematic Review prior to data collection and analysis. This may conveniently be done at [PROSPERO](#)

Description

IL-1 RA update

Inclusion Criteria

peripheral) at any time point and frequency

- Infarct, [neurobehavioural](#) or mortality outcomes where the mean, variance and number of animals per group is reported or can be calculated
- All languages

Exclusion Criteria

Models of haemorrhagic stroke, global ischaemia; in vitro studies

- No control group, review, protocol paper, editorial

Enable machine learning assisted screening?

Enable living systematic search using PubMed?

Cancel

Create

IL-1 RA stroke update

Project Details



Project Details ✎

Name	IL-1 RA stroke update	
Protocol Url	https://drive.google.com/file/d/0B5x-sP1A05kgWWYtX09RejBocKE/view	
Contact Email	gilliancurrie2017@gmail.com	
Number Of Studies	433	View project studies
Creation Date	Wednesday, March 29, 2017	
Completion Date		

Members



Members

Name	Roles	
Gillian Currie	Administration	Edit
Kaitlyn Hair		Edit

Systematic searches



Systematic Searches +

Name	Number of Studies	Library Type	
IL-1 RA update	433	XML Library File	View search studies Remove search

Screening details



Screening Details

Minimum Number of Screeners	2
Project Agreement Ratio	0.333

Stages



[Design Annotation Questions](#)

Stages +

Name	Includes Screening	Number of Annotation Questions

Delete project



Danger Zone ▼

Kaitlyn's Projects

+ Create Project

My Projects

Public Projects



NP Subset Mar 2017 ✓ Invited

Protocol
NP subset



Small ✓ Invited

Protocol
small example



IL-1 RA stroke update ✓ Invited

Protocol
IL-1 RA update



D-galactose-induced brain aging model in rodent: a systematic review and meta-analysis ✓ Invited


Protocol
secondary contact Malcolm Macleod





Depression Test Set 1000 ✓ Invited

Protocol

IL-1 RA stroke update

Project Details 	
Name	IL-1 RA stroke update
Protocol Url <small>*We strongly recommend that you register your Systematic Review prior to data collection and analysis. This may conveniently be done at PROSPERO</small>	https://drive.google.com/file/d/0B5x-sP1A05kgWWYtX09RejBockE/view
Contact Email	gilliancurrie2017@gmail.com
Number Of Studies	433 View project studies
Creation Date	Wednesday, March 29, 2017
Completion Date	

Screening Details 	
Minimum Number of Screeners	2
Project Agreement Ratio	0.333

[Design Annotation Questions](#)

You are not currently a member of this project.

[Register to join](#)


IL-1 RA stroke update

Project Details

Name	IL-1 RA stroke update
Protocol Url	https://drive.google.com/file/d/0B5x-sP1A05kgWWYtX09RejBoc kE/view <small>*We strongly recommend that you register your Systematic Review prior to data collection and analysis. This may conveniently be done at PROSPERO</small>
Contact Email	gilliancurrie2017@gmail.com
Number Of Studies	433 View project studies
Creation Date	Wednesday, March 29, 2017

Members

Name	Roles	
Gillian Currie	Administration	Edit
Kaitlyn Hair		Edit



Name	Number of Studies	Library Type		
IL-1 RA update	433	XML Library File	View search studies	Remove search

Screening Details

Minimum Number of Screeners	2
Project Agreement Ratio	0.333

[Design Annotation Questions](#)

Stages

Name	Includes Screening	Number of Annotation Questions
------	--------------------	--------------------------------

Danger Zone

Systematic search

IL-1 RA stroke update

Project Details

Name

Protocol Url

*We strongly recommend that you register your project prior to data collection and analysis. Review prior to data collection and analysis. Data collection and analysis conveniently be done at PROSPERO

Contact Email

Number Of Studies

Creation Date

Completion Date

Members

Name

Gillian Currie

Administration

Edit

Systematic Searches

Name

Number of Studies

Library Type

Screening Details

Minimum Number of Screeners

2

Project Agreement Ratio

0.333

Add Systematic Search

Search Name

IL-1 RA update

Description

433 studies

Library File Type

EndnoteXml

Study Library

Choose File No file chosen

Cancel

Create



EN EndNote X7 - [Update_1202]

File Edit References Groups Tools Window Help

Quick Search Hide Search Panel

New...
 Open Library... Ctrl+O
 Open Shared Library... Ctrl+Shift+O
 Open Recent
 Close Library Ctrl+W
 Save Ctrl+S
 Save As...
 Save a Copy...
 Revert
 Share...
 Export...
 Import
 Print... Ctrl+P
 Print Preview
 Print Setup...
 Compressed Library (.enlx) ...
 Exit Ctrl+Q

Title	Author	Year
Mechanism for IL-1 beta-mediated neovascularization un...	Ama...	2004
HMGB1 is a potent trigger of arthritis	Ande...	2004
Considering cytokine panels	Anis...	2004
63rd Annual Meeting of the American Association for the S...	Anon...	2004
Experimental neuroprotection: Translation to human strok...	Barb...	2004
Interleukin-1 receptor antagonist polymorphism is not asso...	Byun,...	2004
Cardioprotection of interleukin-2 is mediated via kappa-opi...	Cao, ...	2004
IL-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RA) gen...	Gror...	2004
Inflammatory gene profiling in the developing mouse brain...	Hedtj...	2004
Enhanced inhibitory effect of 5-hydroxytryptamine on nitri...	Hiraf...	2004
IL-1 activation of NF-kappaB signaling pathway in neonatal ...	Hu, X...	2004
Role of interleukin-1 beta in the pathogenesis of diabetic r...	Kowl...	2004

333
 344
 44
 330
 337
 329
 335
 341
 338
 331
 339
 340
 334
 342
 522
 515

EN Export file name: Update_1202

Save in: Desktop

Recent Places


- Libraries System Folder
- Computer System Folder
- Network System Folder
- Desktop
- Libraries
- Computer
- Network
- Desktop 2701317 File folder
- CURRIE Gillian System Folder

File name: Update_1202 Save

Save as type: XML (*.xml) Cancel

Output style: XML (*.xml)

Project Studies



Rows per page: 10 1-10 of 433 studies (filtered from 433 total studies) |< < > >|

Title	Year	Reference Type	Journal	Author	Inclusion Status	Search
Mechanism for IL-1 beta-mediated neovascularization unmasked by IL-1 beta knock-out mice	2004	Journal Article	Journal of Molecular and Cellular Cardiology	K. Amano	Insufficiently Screened	IL-1 RA update
HMGB1 is a potent trigger of arthritis	2004	Journal Article	Journal of Internal Medicine	U. Andersson	Insufficiently Screened	IL-1 RA update
Considering cytokine panels	2004	Journal Article	Brain Behavior and Immunity	Hymie Anisman	Insufficiently Screened	IL-1 RA update
63rd Annual Meeting of the American Association for the Surgery of Trauma held jointly with the Japanese Association of Acute Medicine, Maui, Hawaii, USA, September 29-October 2, 2004	2004	Journal Article	Journal of Trauma Injury Infection and Critical Care	Anonymous	Insufficiently Screened	IL-1 RA update
Experimental neuroprotection: Translation to human stroke trials	2004	Book	Maturation Phenomenon in Cerebral Ischemia V	P. A. Barber	Insufficiently Screened	IL-1 RA update
Interleukin-1 receptor antagonist polymorphism is not associated with ischemic stroke in Type 2 diabetes	2004	Journal Article	Diabetologia	S. H. Byun	Insufficiently Screened	IL-1 RA update
Cardioprotection of interleukin-2 is mediated via kappa-opioid receptors	2004	Journal Article	Journal of Pharmacology and Experimental Therapeutics	Chun-Mei Cao	Insufficiently Screened	IL-1 RA update
IL-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RA) gene polymorphism and the clinical course of ischemic stroke (IS)	2004	Journal Article	European Journal of Neurology	G. Gronadzka	Insufficiently Screened	IL-1 RA update
Inflammatory gene profiling in the developing mouse brain after hypoxia-ischemia	2004	Journal Article	Journal of Cerebral Blood Flow and Metabolism	M. Hedtjarn	Insufficiently Screened	IL-1 RA update

Screen for inclusion

200 Screened

233 Remaining

Whole live animal models of ischaemic occlusive stroke of the middle cerebral or anterior cerebral arteries or their branches • Any primary study comparing treatment and control groups • Any mode of delivery of IL-1 RA (e.g. transgenic, viral, peripheral) at any time point and frequency • Infarct, neurobehavioural or mortality outcomes where the mean, variance and number of animals per group is reported or can be calculated • All languages

Models of haemorrhagic stroke, global ischaemia; in vitro studies • No control group, review, protocol paper, editorial

Excluded

Trimethyltin-evoked apoptosis of murine hippocampal granule neurons is accompanied by the expression of interleukin-1beta and interleukin-1 receptor antagonist in cells of ameboid phenotype, the majority of which are NG2-positive

A. Fiedorowicz, I. Figiel, M. Zaremba, K. Dzwonek, R. Schliebs, B. Oderfeld-Nowak

Brain Research Bulletin, 2008

Abstract:

Interleukin-1beta (IL-1 beta) has been implicated in various neuropathologies, while IL-1 receptor antagonist (IL-1ra) has been shown to reduce neuronal injury. We investigated the pattern of expression of both cytokines in murine hippocampus after trimethyltin (TMT) intoxication. Using a ribonuclease protection assay, we demonstrated induction of transcription of IL-1 beta and IL-1ra 3 days following TMT treatment which correlated with the peak of neuronal apoptosis. At this time, immunocytochemical staining revealed enhanced expression of both cytokines in NG2 proteoglycan expressing ameboid cells located at the site of neurotoxic insult, some of which bound also the microglial marker, lectin. There was some overlap between NG2 and lectin staining. Our results suggest that the two cytokines are involved in apoptotic processes in dentate granule cells and indicate that the pro-apoptotic effect of IL-1 beta prevails over the presumed protective action of IL-1 ra. The novel finding of expression of both cytokines in NG2(+) cells of ameboid phenotype indicates that these cells, through the regulatory roles of pro- and anti-inflammatory cytokines, may be involved in control of neuronal death or survival after injury. (c) 2008 Elsevier Inc. All rights reserved.

Include

Exclude

Next

[View PDF](#)

Screening with the help of machine learning

- For studies with at least **500 hits** can use machine learning to aid screening
- indicate that you want to enable machine learning assisted screening for your project
- NaCTeM created an API that supports this function



Meta-data annotation

Study



Do the authors refer to a protocol?

Disease Model Induction

+ Control Question

+ Non-Control Question

+ Both

These questions will be asked for **each** model induction procedure in the study.

[Non-Control] Type of ischaemia

Type of ischaemia

Treatment

+ Control Question

+ Non-Control Question

+ Both

These questions will be asked for **each** treatment procedure in the study.

[Non-Control] Dose

[Control] Control treatment

Route of delivery

Outcome Assessment



These questions will be asked for **each** outcome assessment procedure in the study.

► Outcomes assessed

Cohort



These questions will be asked for **each** cohort in the study.

Do the authors refer to a protocol?

— Do the authors refer to a protocol?



Accepts only a single answer

Required

Control Type: checkbox

Answer Type: boolean

Add Related

Add Yes Related

Add No Related

Type of ischaemia



Accepts only a single answer

Required

Control Type: dropdown

Answer Type: string

Add Related

Add Permanent Related

Add Temporary Related

Whole live animal models of ischaemic occlusive stroke of the middle cerebral or anterior cerebral arteries or their branches • Any primary study comparing treatment and control groups • Any mode of delivery of IL-1 RA (e.g. transgenic, viral, peripheral) at any time point and frequency • Infarct, neurobehavioural or mortality outcomes where the mean, variance and number of animals per group is reported or can be calculated • All languages

Models of haemorrhagic stroke, global ischaemia; in vitro studies • No control group, review, protocol paper, editorial

Included

Local stimulation of the adenosine A(2B) receptors induces an increased release of IL-6 in mouse striatum: an in vivo microdialysis study

J. F. Vazquez, H. W. Clement, O. Sommer, E. Schulz, D. van Calker

Journal of neurochemistry, 2008

Abstract:

Both adenosine and interleukin-6 (IL-6) have been implicated in the pathophysiology of, e.g., epileptic seizures, traumatic brain injury, and affective disorders. Stimulation of adenosine A(2B) receptors on astrocytes in vitro leads to the increased synthesis and secretion of IL-6. We investigated whether or not activation of adenosine receptors evokes an increase of IL-6 release also in vivo. 5'-N-ethylcarboxamidoadenosine, a non-specific adenosine-agonist or vehicle was administered into the striatum of freely moving mice by reverse microdialysis. A statistical significant increase of the IL-6 concentration in the perfusate was detected already 60 min after 5'-N-ethylcarboxamidoadenosine administration. IL-6 increased progressively and reached a maximum after 240 min. This effect appears to be mediated through adenosine A(2B) receptors since it was counteracted by the specific A(2B) receptor antagonist MRS1706 but not by the specific A(1) receptor antagonist DPCPX. We conclude that adenosine via activation of A(2B) receptors evokes IL-6 release also in vivo.

[View PDF](#)

Include

Exclude

Next



Study

Disease Model Induction

Treatment

Outcome Assessment

Cohort

Experiment

Do the authors refer to a protocol?

Optional comments

Meta-data annotation





Study

Disease Model Induction

Treatment

Outcome Assessment

Cohort

Experiment

Treatment ✕

Control procedure?*

Optional comments

Dose*

100

Optional comments

Units*

mg/kg


Optional comments

Route of delivery*

✕ IP

Optional comments

Automatic Annotation

Project Details 			
Name	SUDEP Stage 2		
Protocol Url <small>*We strongly recommend that you register your Systematic Review prior to data collection and analysis. This may conveniently be done at PROSPERO</small>			
Contact Email	naomiheller@nhs.net		
Number Of Studies	693	Detect Risk of Bias	View project studies
Creation Date	Wednesday, July 13, 2016		
Completion Date			

Outcome data extraction

RA stroke update

Data Extraction for outcome of Cohort 1

Time Point Data

Time	Average	Error
24	18.8	5.6

Time Average Error

Close

Meta-analysis

Select effect size measure

- Normalised mean difference
- Standardised mean difference
- Odds ratio

Select comparison

- Analysis of model
- Analysis of intervention

Select data table

- Raw data
- Calculated data

Select heterogeneity estimator

Restricted maximum-likelihood

[User guide](#)

[Data](#)
[Meta-Analysis](#)
[Forest Plot](#)
[Meta-Regression](#)
[Heterogeneity Bar Plot](#)
[Meta-Regression plot](#)
[Funnel Plot](#)
[Trim-and-Fill](#)
[Egger's Regression](#)

Egger's Regression Plot

Show entries

Search:

Pub.ID	Drug	Outcome.Measure	User.Defined.2a	Unit	Entry.Completed	Year	Animal	Type.of.Ischaemia	Route.of.Drug.Delivery
64	IL1-RA	Infarct Volume	Protein	?g	TRUE	1996	Rat	Permanent	ICerebVentricular
10	IL1-RA	Infarct Volume	Protein	?g	TRUE	2003	Rat	Temporary	ICerebVentricular
117	IL1-RA	Infarct Volume	Protein	?g	TRUE	1997	Rat	Permanent	Stereotactic
117	IL1-RA	Infarct Volume	Protein	?g	TRUE	1997	Rat	Permanent	Stereotactic
64	IL1-RA	Infarct Volume	Protein	?g	TRUE	1996	Rat	Permanent	ICerebVentricular
1001	IL1-RA	Infarct Volume	Protein	unknown	TRUE	2008	Rat	Temporary	IVenous
117	IL1-RA	Infarct Volume	Protein	?g	TRUE	1997	Rat	Permanent	Stereotactic
117	IL1-RA	Infarct Volume	Protein	?g	TRUE	1997	Rat	Permanent	Stereotactic
64	IL1-RA	Infarct Volume	Protein	?g	TRUE	1996	Rat	Permanent	ICerebVentricular
10	IL1-RA	Infarct Volume	Protein	?g	TRUE	2003	Rat	Temporary	ICerebVentricular

Showing 1 to 10 of 65 entries

[Previous](#)
[1](#)
[2](#)
[3](#)
[4](#)
[5](#)
[6](#)
[7](#)
[Next](#)

Data

Meta-Analysis

Forest Plot

Meta-Regression

Heterogeneity Bar Plot

Meta-Regression plot

Funnel Plot

Trim-and-Fill

Egger's Regression

Egger's Regression Plot

Select effect size measure

- Normalised mean difference
- Standardised mean difference
- Odds ratio

Select comparison

- Analysis of model
- Analysis of intervention

Select data table

- Raw data
- Calculated data


Select heterogeneity estimator

Restricted maximum-likelihood

[User guide](#)

Launch Meta-Analysis App

Predicted time frame using SyRF





10,000 hit project

Predicted time frame using SyRF




SYSTEMATIC
Review Facility






SyRF Architecture






Future considerations for SyRF

- SyRF is a living system and can be adapted as new methods and tools are introduced
 - Scalable
 - Adaptable
 - Future proof
 - Sustainable

Tools under development...






Thank you

CAMARADES group



Emily Sena
Malcolm Macleod
Gillian Currie
Sarah McCann
Jing Liao
Christopher Sena
Paula Grill
Kaitlyn Hair
Qianying Wang

Zsanett Bahor (PhD)
Alexandra Bannach-Brown (PhD)



NC
3R^s

National Centre
for the Replacement
Refinement & Reduction
of Animals in Research